Tumoricidal and Radiosensitizing Effects of Onconase; Studies in Human Prostate Carcinoma, Lung Adenocarcinoma and Rat Hepatoma.BLOOMFIELD, N.J.--(BUSINESS WIRE)--Oct. 7, 1999-- Alfacell Corporation (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:ACEL ACEL Australian Council for Educational Leaders (Australia) ACEL Aerospace Crew Equipment Laboratory ACEL Alternating Current Electro-Luminescent ). Independent in vivo studies showed that ONCONASE(R) was significantly more effective than the control treatment in inhibiting tumor growth in transplanted human and murine tumor models. Furthermore, researchers measured changes in several important physiological parameters of tumors. ONCONASE significantly lowered tumor interstitial fluid pressure (TIFP TIFP Tactical Intelligence Fusion Prototype ); increased tumor blood flow (TBF TBF - Mean Time Between Failures ), and increased median tumor partial oxygen pressure (pO2). These results will be presented at the 41st Annual Scientific Meeting of The American Society For Radiology and Oncology (ASTRO) to be held from October 31st to November 4th,1999, in San Antonio, Texas “San Antonio” redirects here. For other uses, see San Antonio (disambiguation). San Antonio is the second most populous city in Texas, the third most populous metropolitan area in Texas, and is the seventh most populous city in the United States. As of the 2006 U.S. . "Hypoxic (oxygen-starved) tumor cells are known to be resistant to radiation therapy. Therefore, ONCONASE, by increasing both TBF and tumor pO2, has demonstrated potential as a novel radiation enhancer. Further studies of radiation response in vivo are warranted," stated Dr. Intae Lee of the University of Pennsylvania School of Medicine The University of Pennsylvania's School of Medicine, presently located in the University City section of Philadelphia, Pennsylvania, was the United States's first school of medicine, founded at the College of Philadelphia, as the University was then called. , Department of Radiation Oncology, Philadelphia. Elevated TIFP is one of the major causes for inadequate drug delivery into solid tumors. These results further support and emphasize the potential benefit of ONCONASE as a new therapeutic agent in cancer treatment. Results of the TIFP studies are scheduled for publication in the September issue in the journal of Clinical Cancer Research. Alfacell Corporation is a leader in the development of ribonucleases (RNases) for therapeutic applications. ONCONASE, an anti-tumor agent is currently being investigated in Phase III clinical trials in patients with unresectable malignant mesothelioma. Alfacell is located in Bloomfield, N.J., and the Company's common stock is traded in the over-the-counter market under the symbol "ACEL". |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion